Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
Diagnosis of meningeal localization of lymphoid malignancies by means of cytologic examination of the cerebrospinal fluid (CSF) can be difficult. Thus far no reliable CSF tumor markers have been identified. CD27 is a transmembrane disulfide-linked 55-kD homodimer present on most peripheral blood T cells and on a subset of B cells. CD27 is also expressed on human malignant B cells and high levels of soluble CD27 can be present in the serum of patients with B-cell malignancies. The aim of this study is to determine prospectively the diagnostic value of CSF sCD27 as a tumor marker in patients with meningeal localization of lymphoid malignancies. CSF sCD27 levels were determined by sandwich enzyme-linked immunosorbent assay. The optimal cut-off value using receiver operator characteristics curves was found to be 10 U/mL. sCD27 levels were normal in all 50 control patients (lumbar disc protrusion) and in 39 of 40 samples obtained from patients with either solid tumors or acute myeloid leukemia. Of 104 CSF samples from 70 children with acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) undergoing routine central nervous system (CNS) staging, sCD27 was false positive and false negative in only one sample each. In 70 samples from 45 patients suspected of meningeal localization of ALL or NHL, the sCD27 test had an excellent sensitivity (100%) and specificity (82%). In 7 patients with positive CSF studied longitudinally, sCD27 levels correlated very well with remission and relapse. sCD27 levels were not nonspecifically increased by the administration of cytostatic drugs. Finally, sCD27 was also elevated in the 4 patients studied with primary central nervous system lymphoma (PCNSL). CSF sCD27 is a promising tumor marker in patients with either meningeal localization of lymphoid malignancies or PCNSL, and can be useful in the differential diagnosis of CNS involvement by either lymphoid malignancies or solid tumors.
Kersten
M J
MJ
Department of Hematology and Neurology, Academic Medical Centre, Amsterdam, The Netherlands.
Evers
L M
LM
Dellemijn
P L
PL
van den Berg
H
H
Portegies
P
P
Hintzen
R Q
RQ
van Lier
R A
RA
von dem Borne
A E
AE
van Oers
R H
RH
D000328:Adult; D000951:Antigens, Neoplasm / Q000134:cerebrospinal fluid*; D014408:Biomarkers, Tumor / Q000134:cerebrospinal fluid*; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000473:pathology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis*; D002648:Child; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay; D005189:False Positive Reactions; D006801:Humans; D017254:Leukemic Infiltration / Q000134:cerebrospinal fluid*; D008228:Lymphoma, Non-Hodgkin / Q000134:cerebrospinal fluid* / Q000473:pathology*; D008578:Meninges / Q000473:pathology*; D009361:Neoplasm Invasiveness / Q000175:diagnosis*; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000134:cerebrospinal fluid* / Q000473:pathology*; D011446:Prospective Studies; D012372:ROC Curve; D012074:Remission Induction; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000134:cerebrospinal fluid*; D001613:beta 2-Microglobulin / Q000134:cerebrospinal fluid
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002556:Cerebrospinal Fluid Proteins; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D001613:beta 2-Microglobulin